• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Regulatory/Compliance

South African government forms medical device and drug market regulatory body

June 15, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group The South African government has formed a new agency to oversee new medical device and pharmaceutical regulatory systems being developed in the country. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those […]

Filed Under: Regulatory/Compliance Tagged With: blog, Emergo Group

Lilly wins FDA nod for Humalog pre-filled Junior KwikPen device

June 14, 2017 By Sarah Faulkner

Eli Lilly

Eli Lilly (NYSE:LLY) said today that the FDA approved its Humalog Junior KwikPen for the treatment of diabetes. The device is a pre-filled pen with half-unit dosing capabilities, which Eli Lilly said gives patients access to finer dose adjustment. “We are pleased to be able to meet the needs of people who prefer a prefilled […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: Eli Lilly & Co.

Cleveland Clinic spinout Infuseon wins FDA nod for CNS drug delivery device

June 13, 2017 By Sarah Faulkner

Infuseon Therapeutics

Cleveland Clinic spinout Infuseon Therapeutics said today that its novel central nervous system delivery device won 510(k) clearance from the FDA as a therapeutic delivery device. The company’s Cleveland Multiport Catheter, which won FDA clearance in March, was designed to effectively deliver therapeutics to the brain. Usually, the blood brain barrier prevents drugs delivered in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Cleveland Clinic, infuseontherapeutics

Braeburn, Knight seek Health Canada nod for opioid dependence implant

June 13, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence. In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada. Braeburn’s […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Knight Therapeutics

Milestone Scientific wins 510(k) clearance for epidural anesthesia system

June 12, 2017 By Sarah Faulkner

Milestone Scientific

Milestone Scientific (NYSE:MLSS) said today that its CompuFlo epidural computer-controlled anesthesia system won 510(k) clearance from the FDA. The Livingston, N.J.-based company’s CompuFlo Epidural instrument uses dynamic pressure sensing to help anesthesiologists correctly identify the epidural space and significantly reduce complications in real-time, according to Milestone. Shares in the company jumped up 18% today, trading […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: milestonescientific

Germany to apply to host European drug agency after Brexit

June 12, 2017 By Sarah Faulkner

European Medicines Agency

Germany plans to apply to host the London-based European Medicines Agency and the European Banking Authority after Britain leaves the European Union, Reuters reported. “Germany is throwing its hat into the ring for both agencies – with Bonn for the European Medicines Agency EMA and with Frankfurt for the European Banking Authority EBA,” government spokesman Steffen Seibert […]

Filed Under: Featured, Pharmaceuticals, Regulatory/Compliance

Medtech stories we missed this week: June 9, 2017

June 9, 2017 By Danielle Kirsh

missed medtech

From 3M’s expanded 510(k) clearance for its Tegaderm dressing to Medtronic and Acacia burying the hatchet, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. InspireMD inks Taiwanese distro deal for CGuard InspireMD announced in a June 8 press release that it has signed a distribution deal with […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Research & Development Tagged With: 3M, Acacia Research Corp., Active Implants, Advanced Cooling Therapy, Attune Medical, Exactech Inc., HLT, InspireMD, medtech, Medtronic

Johnson & Johnson wins last regulatory nod needed for Actelion acquisition

June 9, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said today that the European Commission approved its acquisition of Swiss biotech Actelion. The regulatory nod was the last approval needed to complete the company’s transaction. The U.S. healthcare giant added that it expects the settlement of the $30 billion all-cash tender offer on June 16. The EU commission set conditions […]

Filed Under: Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

OncoSec wins orphan drug status for melanoma therapy

June 9, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS) said today that its DNA-based intratumoral cancer immunotherapy, pIL-12, won orphan drug designation from the FDA for the treatment of unresectable metastatic melanoma. The drug, tavokinogene telsaplasmid, is the biologic agent delivered using OncoSec’s ImmunoPulse IL-12 electroporation device. The company’s device delivers a sequence of short-duration electrical pulses to increase the cancer […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Wall Street Beat Tagged With: OncoSec Medical

FDA asks Endo to pull Opana from the market over concerns of abuse

June 9, 2017 By Sarah Faulkner

Endo Pharmaceuticals

The FDA asked Endo Pharmaceuticals (NSDQ:ENDP) to pull its opioid pain med, Opana ER, from the market, saying that the benefits of the abuse-deterrent drug no longer outweigh the risks. The move marks the 1st time the federal regulatory watchdog has urged a company to remove an opioid painkiller due to concerns of abuse. “We are facing […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Endo Pharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 94
  • Page 95
  • Page 96
  • Page 97
  • Page 98
  • Interim pages omitted …
  • Page 113
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS